COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants

As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest in the longevity of immune protection, especially with regard to increasingly infectious virus variants. Neutralizing antibodies (Nabs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are promising cor...

Descripción completa

Detalles Bibliográficos
Autores principales: Junker, Daniel, Dulovic, Alex, Becker, Matthias, Wagner, Teresa R., Kaiser, Philipp D., Traenkle, Bjoern, Kienzle, Katharina, Bunk, Stefanie, Struemper, Carlotta, Haeberle, Helene, Schmauder, Kristina, Ruetalo, Natalia, Malek, Nisar, Althaus, Karina, Koeppen, Michael, Rothbauer, Ulrich, Walz, Juliane S., Schindler, Michael, Bitzer, Michael, Göpel, Siri, Schneiderhan-Marra, Nicole
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062870/
https://www.ncbi.nlm.nih.gov/pubmed/35505068
http://dx.doi.org/10.1038/s41598-022-10987-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9062870/
https://www.ncbi.nlm.nih.gov/pubmed/35505068
http://dx.doi.org/10.1038/s41598-022-10987-2

Ejemplares similares